Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

First-in-human Evaluation of the SELUTION DCB, a Novel Sirolimus Coated Balloon in Peripheral Arteries

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02941224
Recruitment Status : Unknown
Verified May 2017 by M.A. Med Alliance S.A..
Recruitment status was:  Active, not recruiting
First Posted : October 21, 2016
Last Update Posted : June 1, 2017
Sponsor:
Information provided by (Responsible Party):
M.A. Med Alliance S.A.

Brief Summary:

The primary objective of the Clinical Investigation is to assess the clinical safety and the inhibition of restenosis of the Investigational Device in the treatment of de-novo occluded/stenotic or re-occluded/restenotic lesions of the superficial femoral and/or popliteal arteries.

The primary endpoint of the Clinical Investigation is Late Lumen Loss (LLL) of the target lesion, as measured by Quantitative Vascular Angiography (QVA) at 6 months post-index procedure.


Condition or disease Intervention/treatment Phase
Patients With Peripheral Artery Disease in the SFA or PA Device: SELUTION DCB (sirolimus coated balloon) Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: SELUTION™ Sirolimus Coated PTA Balloon Catheter Prospective, Controlled, Multi-Center, Open, Single-Arm Clinical Investigation for the Treatment of Patients With Femoropopliteal Artery Lesions With a Novel Drug Coated Balloon
Study Start Date : October 2016
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : June 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Sirolimus

Arm Intervention/treatment
Experimental: SELUTION DCB
The SELUTION™ DCB (coated with sirolimus) is intended for use as a Percutaneous Transluminal Angioplasty (PTA) balloon catheter to dilate de-novo or restenotic vascular lesions, for the purpose of improving limb perfusion and decreasing the incidence of restenosis.
Device: SELUTION DCB (sirolimus coated balloon)



Primary Outcome Measures :
  1. Late Lumen Loss (LLL) of the target lesion, as measured by Quantitative Vascular Angiography (QVA) [ Time Frame: 6 Months (plus or minus 30 days) ]

Secondary Outcome Measures :
  1. Device success [ Time Frame: index procedure ]
    defined as successful delivery, inflation, deflation and retrieval of the Investigational Device

  2. Procedural success [ Time Frame: index procedure ]
    defined as final residual stenosis of ≤ 30% of the target lesion, as measured by QVA

  3. Clinical success [ Time Frame: within 24 hours post-index procedure ]
    defined as procedural success with no MAE noted

  4. Freedom from device- and procedure- related death [ Time Frame: 30 days ]
  5. Freedom from Major Adverse Event (MAE) [ Time Frame: 6 Months (plus or minus 30 days) ]
    defined as composite rate of Cardio-Vascular (CV) mortality, index limb amputation, target lesion thrombosis and clinically driven Target Lesion Revascularization (TLR)

  6. Primary Patency (PP) [ Time Frame: discharge, 6, 12 and 24 Months (plus or minus 30 days) ]
    defined as freedom from clinically driven Target Lesion Revascularization (TLR) and freedom from restenosis as determined by Duplex Ultrasound (DUS) with a Peak Systolic Velocity Ratio (PSVR) < 2.5 of the target lesion

  7. Composite of freedom from index limb amputation and clinically driven Target Vessel Revascularization (TVR) [ Time Frame: 12 and 24 Months (plus or minus 30 days) ]
  8. Angiographic Binary Restenosis (ABR) [ Time Frame: 6 Month (plus or minus 30 days) ]
    defined as > 50% diameter stenosis of the target lesion, as measured by QVA

  9. Change of Rutherford Classification as compared to baseline [ Time Frame: at 6, 12 and 24 months (plus or minus 30 days) ]
  10. Change of Ankle Brachial Index (ABI) as compared to baseline [ Time Frame: at 6, 12 and 24 months (plus or minus 30 days) ]
  11. Change in functional status measured by changes in the Walking Impairment compared to baseline [ Time Frame: at 6, 12 and 24 months (plus or minus 30 days) ]
  12. Change in functional status measured by changes in the general health-related Quality of Life measured by changes in EQ-5D-5L questionnaire compared to baseline [ Time Frame: at 6, 12 and 24 months (plus or minus 30 days) ]
  13. User Acceptance Testing (UAT) questionnaire [ Time Frame: index procedure ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients who are mentally and linguistically able to understand the aim of the Clinical Investigation and to show sufficient compliance in following the Clinical Investigation Plan.
  2. Patients must agree to return for all required post-index procedure follow-up visits.
  3. Patients are able to verbally acknowledge an understanding of the associated risks, benefits, and treatment alternatives to therapeutic options of the Clinical Investigation. Patients, by providing their informed consent, agree to these risks and benefits as stated in the patient informed consent document.
  4. Patients have a documented diagnosis of Peripheral Arterial Disease (PAD) classified as Rutherford class 2-3-4 in the Superficial Femoral Artery (SFA) and/or Popliteal Artery (PA). Patients with a documented diagnosis of PAD classified as Rutherford class 2, may only be included in case conservative and medicinal treatment have proved ineffective in these patients.
  5. Patients are able to walk without assistive devices such as walker or cane.
  6. Patients are eligible for peripheral revascularization by means of PTA.
  7. The target vessel reference diameter must be ≥ 3.0 and ≤ 7.0 mm.
  8. The target lesion length must be ≤ 15 cm and stenosed or occluded.
  9. The target lesion must be in a native, non-stented SFA and/or PA target vessel and located ≥ 1 cm below the Common Femoral Artery (CFA) bifurcation and terminate distally ≥ 1 cm above the origin of the Tibial-Peroneal (TP) trunk.
  10. Treatment of multiple target lesions is allowed, as long as the composite target lesion length is ≤ 15 cm and the target lesions can be treated with a maximum of 2 overlapping Investigational Devices.
  11. The target lesion must either be de-novo or restenotic (stenosis ≥ 70% diameter reduction or occlusion by visual estimate). If the target lesion is restenotic, the prior PTA must have been done > 30 days prior-index procedure.
  12. The target lesion must have been successfully crossed with a guide wire and there must be successful pre-dilatation of the target lesion, in the absence of early recoil, significant remaining stenosis or flow-limiting dissection.
  13. There must be a patent (< 50% stenosis) inflow artery, as confirmed by angiography. Treatment of inflow disease during the index procedure is allowed. Patients with flow-limiting inflow lesions can be included, if inflow lesions have been treated (use of DES or DCB not allowed) successfully (attainment of residual diameter stenosis ≤ 30% without major vascular complications).

There must be at least 1 patent (< 50% stenosis) native outflow artery to the ankle, as confirmed by angiography. Treatment of outflow disease during the index procedure is NOT permitted.

Exclusion Criteria:

  1. Patients with a known hypersensitivity or contraindication to aspirin, heparin, other anticoagulant/anti-platelet therapies, Sirolimus (or analogs) or sensitivity to contrast media that cannot be adequately pre-medicated.
  2. Patients with an obligatory need of cumarine or other anticoagulants (e.g. Novel Oral Anticoagulant (NOAC) drugs).
  3. Patients with any contraindications as mentioned in the Instructions for Use (IFU) of the Investigational Device.
  4. Patients with a life expectancy, from the Investigator's opinion, of less than 3 years.
  5. Patients that are currently participating in other clinical investigations involving any investigational drug or device that may potentially confound the results of the Clinical Investigation, or that would limit the patient's compliance with the follow-up requirements of the Clinical Investigation.
  6. Patients with a history of Myocardial Infarction (MI), thrombolysis or angina within 30 days prior-index procedure.
  7. Patients with a history of major disabling stroke within 3 months prior-index procedure.
  8. Patients with any type of previous or planned surgical or interventional procedure within 15 days prior- and/or within 30 days post-index procedure.
  9. Patients with a presence or history of severe renal failure (Glomerular Filtration Rate (GFR) ≤ 30 ml/min).
  10. Patients who have undergone prior vascular surgery of the SFA and/or PA in the index limb to treat atherosclerotic disease.
  11. Patients with clinically significant aneurysmal disease of the iliac, femoral or popliteal artery and patients with a history of clinically significant abdominal aortic aneurysm.
  12. Treatment of the contralateral limb during the same index procedure or within 30 days post-index procedure in order to avoid confounding complications.
  13. Patients under administrative or judicial custody (§20 Act on Medical Devices, Germany).
  14. Composite target lesion length is > 15 cm.
  15. Treatment of target lesion(s) that requires more than 2 overlapping Investigational Devices.
  16. A COMPLIANCE360-Score of 3 or higher, showing a (moderately) severe circumferentially calcified target lesion as displayed on plain x-ray prior to the index procedure expected for early recoil and imperative need of plaque modulation or stenting as judged by the investigator prior to pre-dilatation.
  17. Significant inflow disease or treatment of inflow disease during index procedure not successful.
  18. Known inadequate distal outflow (> 50 % stenosis of distal popliteal and/or all three tibial vessels), or planned treatment of vascular disease distal to the target lesion post-index procedure.
  19. Known required use of adjunctive treatment modalities (laser, atherectomy, cryoplasty, scoring/cutting balloon, etc.).

Remaining acute or sub-acute thrombus in the target vessel.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02941224


Locations
Layout table for location information
Germany
Universitäts-Herzzentrum Freiburg-Bad Krozingen
Bad Krozingen, Baden Wuertemberg, Germany, 79189
Radiologische Gemeinschaftspraxis Ihre-Radiologen Franziskus - Krankenhaus Berlin
Berlin, Germany, 10787
Vivantes Klinikum Neukölln
Berlin, Germany, 12351
Evangelisches Krankenhaus Hubertus
Berlin, Germany, 14129
Sponsors and Collaborators
M.A. Med Alliance S.A.
Investigators
Layout table for investigator information
Principal Investigator: Thomas Zeller, Prof Dr Med Universitäts-Herzzentrum Freiburg-Bad Krozingen

Layout table for additonal information
Responsible Party: M.A. Med Alliance S.A.
ClinicalTrials.gov Identifier: NCT02941224     History of Changes
Other Study ID Numbers: SP-1001
First Posted: October 21, 2016    Key Record Dates
Last Update Posted: June 1, 2017
Last Verified: May 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Peripheral Arterial Disease
Atherosclerosis
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Peripheral Vascular Diseases
Sirolimus
Everolimus
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Antifungal Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs